You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

926 Results
Document
Mar 2020
Document
Mar 2020
Document
Mar 2020
Document
Mar 2020
Document
Mar 2020
Regimen
Cancer Type:
Genitourinary, 
Prostate
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    darolutamide - For the treatment of high risk non-metastatic castration resistant prostate cancer (nmCRPC) according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
darolutamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2024
Document
Mar 2020
Document
Mar 2020
Statistical Reports
Document
Apr 2020
Document
Apr 2020

Pages